We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT Clinical has announced the extension of its services via its OCT Oncology™ solution, to address needs in oncology clinical research, with a special focus on emerging biotechs.
To accomodate the specialized attention emerging oncology therapies often require, OCT Clinical focuses on accelerated access, speedy enrollment, and ultimately cost efficiency.
Read the full article at Applied Clinical Trials official website. [1]
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
